Pharma, Security and Profits
Dear Government Inc. readers, please take a look at this press release about a Defense Threat Reduction Agency contract with a company called Peregrine Pharmaceuticals.
By the capacious standards of federal spending, it's not much. Only up to $44.4 million. But I love it for two reasons.
1. This line, which tells such a big story about profiting from threats: "According to Peregrine, the DTRA biodefense contract award has the potential to create long-term value for the company, including generating future potential revenues from government stockpiling to combat bioterrorism threats."
2. I love one of the words it uses: bavituximab. What the....?
Here's what Wikipedia has to say about that word. "Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4."
One reader thought it would increase the sophistication of the posting if I included this link from the company's Web page, so here it is.
Government Inc. wonders whether we should do a long, long list of all the threats the government is paying contractors to consider. Might be edifying. On the other hand, might be really, really scary. Maybe we'll hear about some of them in the run up to the election.
Please email us to report offensive comments.
Posted by: Nick | July 9, 2008 8:36 AM
Posted by: Bavituximab | July 9, 2008 10:52 AM
Posted by: NCB | July 9, 2008 11:00 AM
Posted by: Someone | July 10, 2008 11:12 AM
Posted by: LALA | July 11, 2008 12:42 AM
Posted by: GrowinBrain | July 11, 2008 10:44 AM
Posted by: thesheeplion | July 11, 2008 12:25 PM
Posted by: DR Carl | July 11, 2008 1:39 PM
Posted by: Sam | July 12, 2008 4:16 PM
Posted by: RuckSack | July 18, 2008 10:53 AM
The comments to this entry are closed.